Merger/Buyout

And this is why BW wanted the company to sell right before launch. Who in there right mind would buy this mess.

 

Correct!
Two Things:
1) BW was a grifter, a phony, a charleton who got where he got selling unknowing investors/boards that he was a genius because of his experience at Genentech (as if that company's success was because of him)
2) In the summer of 2016 the stock was cooking based on takeover rumors (Shire). But, no VP of M&A (that's Mergers & Acquisitions for you home gamers) would ever put his or her career on the line by recommending buying this company; either for the current product, or the blah pipeline. And none of them will now either.

 

Huh? makes no sense

 

LOL ! Love it!
Wish you would’ve been there when BW was telling the commercial team that Tymlos had the same market potential that Humira had when it was first approved. HUMIRA!! The biggest selling drug in the history of Biopharma.
Grifter, charleton, phony, huckster. And so was that f*cking egomaniacal idiot DS and his butt licker, KC.

 

obviously an ex-employee from over 3 years ago. Who cares?

 

Guess again. Hint: your close but not ex actly correct

 

Since the turn over rate is about 60% the thought that being an ex employee would make you respond to comment negatively is ridiculous. The entire sales force has been turned over and the Pharm industry is more then aware of the lack of leadership and focus.

 

Huh? Makes no sense.

 

Makes no sense to whom..quit trolling Radius HR. There is nothing here to stay for, most waiting to leave after end of year when hiring process for other companies restart. Oh that will be the 3rd or 4th person a physician will see from Radius. Lies, misrepresented ideas, goals set with thought or concern to patient length of therapy. JK and JH just waiting for golden parachute. Do you have one?

 

Now that makes sense. Well said. But those two won’t get chutes. Someone would have to buy us for that to happen.

 

Be more concerned over yesterday's earnings call.

 

why? I see it's way down.. But what part of it is concerning? Patch delay?

 

Read the transcript from the earnings call...
New focused strategy
Patch at least two years away
No more Oncology studies (two years for current data):
"In line with our refined strategy focus, we will not initiate further clinical development for elacestrant or 140 beyond the ongoing Emerald study. With our new strategy, we aim to enhance value for our assets and allocate our resources efficiently on our core strength to maximize opportunities for our business, shareholders and patients."--JH
-Down 20%-
Leadership fails again

 

Why did anything this company would make a go at it. I hope everyone who is still an employee looks serious at other employment options. There are more then 10 companies in my geography looking for sales individuals. You do not think JK is aggressive looking, someone said the company has assets until spring 2020, think that is accurate. The worse part is the horrible way in which they treat every employee with follow-up from HR. In the mean time they are stealing money from hard working individuals who are making a company profit and changing the rules each quarter. Folks...move on. You will be happier with a company that has respect for your work ethic and integrity .

 

Exactly. Absolutely nothing worth buying here.

 

JK: very disappointing.

 

Delayed patch certainly not a good thing, but the selling off of the oncology assets is the end for RDUS. it's not just "no more oncology studies for 2 years" it's no more oncology.

 

just another day in paradise. Radius will overcome this wasting more money dont you worry.

 

They will not be around 2 years.

 

Cool buyout